Cullinan Therapeutics, Inc. (CGEM) on Tuesday said the U.S. Food and Drug Administration has accepted a New Drug Application for zipalertinib to treat patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
The FDA set a Prescription Drug User Fee Act target action date of February 27, 2027.
The application is backed by Phase 2b data from the REZILIENT1 trial, where zipalertinib met its primary endpoint by achieving a strong objective response rate in previously treated patients.
Zipalertinib is being developed by Taiho Oncology, Inc., and its parent company, Taiho Pharmaceutical Co., Ltd. globally, and in partnership with Cullinan Therapeutics in the United States.
Cullinan shares gained more than 2% in pre-market trading after closing at $13.25 on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.